ArticleDiabetes technology & therapeutics2019
Hemoglobin A1c Trajectory in Pediatric Patients with Newly Diagnosed Type 1 Diabetes.
Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Sustained HbA1c Improvements Over 36 Months in Youth in the Teamwork, Targets, Technology, and Tight Control (4T) Study.The Journal of clinical endocrinology and metabolism · 2026Article
- Toward a Clinically Actionable, Electronic Health Record-Based Machine Learning Model to Forecast 90-Day Change in Hemoglobin AJMIR diabetes · 2025Article
- Disparities in Time to Technology Initiation in the Year Following Diagnosis of Type 1 Diabetes among Youth: A Retrospective Cohort Study.Journal of diabetes science and technology · 2025Article
- Early Continuous Glucose Monitor Use in Children and Adolescents With Type 1 Diabetes: Rates of Initiation and Impact on Glycemic Outcomes.Diabetes care · 2025Observational
- ROCKET T1D Remote Patient Monitoring Program: Launching Diabetes Management Habits in New-Onset Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- A Retrospective Cohort Study of Racial/Ethnic and Socioeconomic Disparities in Initiation and Meaningful Use of Continuous Glucose Monitoring Among Youth With Type 1 Diabetes.Journal of diabetes science and technology · 2024Article
- Electronic Dashboard to Improve Outcomes in Pediatric Patients With Type 1 Diabetes Mellitus.Journal of diabetes science and technology · 2024Article
- Equitable implementation of a precision digital health program for glucose management in individuals with newly diagnosed type 1 diabetes.Nature medicine · 2024Article
- Early increase in HbA1c trajectory predicts development of severe microangiopathy in patients with type 1 diabetes: the VISS study.BMJ open diabetes research & care · 2024Observational
- ROUTE-T1D: A behavioral intervention to promote optimal continuous glucose monitor use among racially minoritized youth with type 1 diabetes: Design and development.Contemporary clinical trials · 2024Article
- Role and Perspective of Certified Diabetes Care and Education Specialists in the Development of the 4T Program.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- A comparative study using insulin pump therapy and continuous glucose monitoring in newly diagnosed very young children with type 1 diabetes: it is possible to bend the curve of HbA1c.Acta diabetologica · 2023Observational
- Visit-to-visit HbA1c variability is associated with aortic stiffness progression in participants with type 2 diabetes.Cardiovascular diabetology · 2023Article
- Disparities in Hemoglobin A1c Levels in the First Year After Diagnosis Among Youths With Type 1 Diabetes Offered Continuous Glucose Monitoring.JAMA network open · 2023Article
- Roadmap to Continuous Glucose Monitoring Adoption and Improved Outcomes in Endocrinology: The 4T (Teamwork, Targets, Technology, and Tight Control) Program.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
- Algorithm-Enabled, Personalized Glucose Management for Type 1 Diabetes at the Population Scale: Prospective Evaluation in Clinical Practice.JMIR diabetes · 2022Article
- Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Type 1 Diabetes: the Pilot 4T Study.The Journal of clinical endocrinology and metabolism · 2022Article
- Early Initiation of Intermittently Scanned Continuous Glucose Monitoring in a Pediatric Population With Type 1 Diabetes: A Real World Study.Frontiers in endocrinology · 2022Article
- Adding glycemic and physical activity metrics to a multimodal algorithm-enabled decision-support tool for type 1 diabetes care: Keys to implementation and opportunities.Frontiers in endocrinology · 2022Article
- Clinically Serious Hypoglycemia Is Rare and Not Associated With Time-in-range in Youth With New-onset Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite advances in diabetes technology and treatment, a majority of children and adolescents with type 1 diabetes (T1D) fail to meet hemoglobin A1c (HbA1c) targets. Among high-income nations, the United States has one of the highest mean HbA1c values. We tracked the HbA1c values of 261 patients diagnosed with T1D in our practice over a 2.5-year period to identify inflection points in the HbA1c trajectory. The HbA1c declined until 5 months postdiagnosis. There was a rise in the HbA1c between the fifth and sixth month postdiagnosis. The HbA1c continued to steadily rise and by 18 months postdiagnosis, the mean HbA1c was 8.2%, which is also our clinic mean. Understanding the HbA1c trajectory early in the course of diabetes has helped to identify opportunities for intensification of diabetes management to flatten the trajectory of HbA1c and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.